Arama

EISSN 2148-5607

TJG IS INDEXED IN WEB OF SCIENCE AND PUBMED IMPACT FACTOR: 1.107

Turkish Journal of Gastroenterology

HIGHLY CITED ARTICLES

Does steatosis affect the performance of diffusion-weighted MRI values for fibrosis evaluation in patients with chronic hepatitis C genotype 4?

By: Besheer, Tarek; Razek, Ahmed Abdel Khalek Abdel; El-Bendary, Mahmoud; et al.

Interleukin-6 and interleukin-17 gene polymorphism association with celiac disease in children

By: Akbulut, Ulas Emre; Cebi, Alper Han; Sag, Elif; et al.

Use of probiotics as an adjuvant to sequential H. pylori eradication therapy: impact on eradication rates, treatment resistance, treatment-related side effects, and patient compliance

By: Cekin, Ayhan Hilmi; Şahinturk, Yasin; Harmandar, Ferda Akbay; et al.

Decreasing prevalence of Helicobacter pylori according to birth cohorts in urban China

By: Yu, Xinjuan; Yang, Xuan; Yang, Tingting; et al.

Role of Th1/Th2 cells and related cytokines in autoimmune hepatitis

By: Behfarjam, Farinaz; Sanati, Mohammad Hossein; Nasseri-Moghaddam, Siavash; et al.

Proton pump inhibitor use for 12 months is not associated with changes in serum magnesium levels: a prospective open label comparative study

By: Bahtiri, Elton; Islami, Hilmi; Hoxha, Rexhep; et al.

Title Keyword Full Text DOI

Authors

Article Type

Article Category

Year

Search Results

Total of 14 results

Ranking

Release Date Sort Sort Article Type

How long should we treat patients with azathioprine/ 6-mercaptopurine before deciding that it is refractory to immunomodulatory treatment?

Gökhan KABAÇAM, Murat TÖRÜNER

(Turk J Gastroenterol 2012; 23: 13-16) DOI: 10.4318/tjg.2012.0617

Abstract Full Text (PDF) Related Articles

Can azathioprine/6-mercaptopurine treatment be withdrawn in patients with response in ulcerative colitis: What is the most appropriate time for this?

Gökhan KABAÇAM, Murat TÖRÜNER

(Turk J Gastroenterol 2012; 23: 17-20) DOI: 10.4318/tjg.2012.0618

Abstract Full Text (PDF) Related Articles

What is the importance of anti-TNF agents in the treatment of luminal (inflammatory type) Crohn's disease?

Gökhan KABAÇAM, Murat TÖRÜNER

(Turk J Gastroenterol 2010; 21: 107-112) DOI: 10.4318/tjg.2010.0066

Abstract Full Text (PDF) Related Articles

How long should we treat patients with azathioprine/ 6-mercaptopurine before deciding that it is refractory to immunomodulatory treatment?

Can azathioprine/6-mercaptopurine treatment be withdrawn in patients with response in ulcerative colitis: What is the most appropriate time for this?

What is the importance of anti-TNF agents in the treatment of luminal (inflammatory type) Crohn's disease?

Effects of polymorphism in G2677T/A triallelic region of MDR1 gene in Turkish patients with inflammatory bowel disease

The effect of rabeprazole alone or in combination with H2 receptor blocker on intragastric pH: A pilot study

Factor V Leiden, prothrombin G20210A and MTHFR gene mutations in inflammatory bowel disease

Two relatives with Caroli’s disease

Serum connective tissue markers as predictors of advanced fibrosis in patients with chronic hepatitis B and D

Association between single nucleotide polymorphisms in prospective genes and susceptibility to ankylosing spondylitis and inflammatory bowel disease in a single centre in Turkey

Diagnosis and treatment of iron deficiency anemia in patients with inflammatory bowel disease and gastrointestinal bleeding: iron deficiency anemia working group consensus report

A rare cause of small bowel obstruction

The influence of disease type and activity to sexual life and health quality in inflammatory bowel disease

2019 Expert opinion on biological treatment use in inflammatory bowel disease management

Population-based assessment of gastrointestinal symptoms and diseases: Cappadocia Cohort, Turkey